Traders should anticipate near-term downward pressure on the stock due to dilution and the history of frequent capital raises. The concurrent warrants could create future overhang. Monitor for continued reliance on dilutive financing as a sign of financial stress.
Price Chart
Executive Summary
Acurx Pharmaceuticals is raising approximately $2.35 million through a registered direct offering of 816,068 shares of common stock and pre-funded warrants for 9,017 shares, priced at $3.03 per share, with concurrent private placement warrants. The net proceeds will be used for general working capital purposes. This is a dilutive capital raise from a company with a history of frequent financings.
Key Facts
- Offering 816,068 shares of common stock and pre-funded warrants for 9,017 shares at $3.03 per share
- Concurrent private placement of warrants for 1,650,170 shares at $2.78 exercise price
- Gross proceeds of approximately $2.5 million before fees and expenses
- Net proceeds expected to be approximately $2.2 million after fees and expenses
- Proceeds to be used for working capital and general corporate purposes
- Company has a history of frequent financings including a $12 million ELOC with Lincoln Park
- Significant dilution of $0.50 per share to new investors
Financial Impact
Raises approximately $2.35 million in net proceeds through issuance of common stock and warrants, resulting in immediate dilution of $0.50 per share to new investors
Risk Factors
- Significant shareholder dilution from the offering
- Potential for future dilution from warrants and convertible securities
- History of frequent financings indicating possible cash flow problems
- Low trading volume and potential liquidity issues
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-044092 |
| Document: 0001104659-26-044092-index-headers.html | 0001104659-26-044092 |
| Document: 0001104659-26-044092-index.html | 0001104659-26-044092 |
| Document: 0001104659-26-044092.txt | 0001104659-26-044092 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 18, 2026 5w ago | EFFECT | $1.39 $1.10 | ▲ +20.86% | ▲ +21.07% | $1.09 (+21.94%) |
Aug 14, 2026 10w ago | Press Release | $1.40 $1.39 | ▼ −0.36% | ▲ +1.63% | $1.09 (−22.22%) |
May 4, 2026 25w ago | S-1 | $2.00 $1.80 | ▲ +10.00% | ▲ +14.95% | $1.09 (+45.75%) |
May 4, 2026 25w ago | S-1 | $2.00 $1.80 | ▲ +10.00% | ▲ +14.95% | $1.09 (+45.75%) |
Apr 16, 2026 27w ago | 8-K | $2.49 $1.99 | ▼ −20.08% | ▼ −25.90% | $1.09 (−56.43%) |
Apr 16, 2026 27w ago | 424B5 | $2.49 $1.99 | ▲ +20.08% | ▲ +25.90% | $1.09 (+56.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers